Antibiotics

Acetylcysteine, antibiotics

To avoid incompatibilities or inactivations, they should be administered separately and at an interval of at least 2 hours

Adefovir dipivoxil [1], aminoglycoside antibiotics ---> SmPC of [1] of EMA

Co-administration of adefovir dipivoxil with intravenous aminoglycosides may increase serum concentrations of either adefovir or the co-administered medicinal product

Ambroxol, antibiotics

Increased concentration of antibiotic in pulmonary tissue.

Amikacine [1], aminoglycoside antibiotics ---> SmPC of [1] of eMC

Concurrent or serial use of amikacin with other neurotoxic, ototoxic or nephrotoxic agents should be avoided either systemically or topically because of the potential for additive effects.

Amikacine, polypeptide antibiotics

The administration concurrent or sequential of polypeptide antibiotics with aminoglycoside antibiotics may increase the risk of nephrotoxicity and/or of neuromuscular blockade that can cause respiratory depression or paralysis (apnea)

Aminoglycoside antibiotics [1], cephalexin ---> SmPC of [1] of eMC

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, amoxicillin

A synergistic effect may occur.

Aminoglycoside antibiotics, amphotericin ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with amphotericin may increase the risk of nephrotoxicity

Aminoglycoside antibiotics, anticholinesterase

Neuromuscular effects

Aminoglycoside antibiotics, antihistamines

Antihistaminics may mask the ototoxic effects of other drugs

Aminoglycoside antibiotics, ataluren [2] ---> SmPC of [2] of EMA

Ataluren was found to increase nephrotoxicity of intravenous aminoglycosides. The co-administration of these medicinal products with ataluren should be avoided

Aminoglycoside antibiotics, atracurium [2] ---> SmPC of [2] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with antibiotics

Aminoglycoside antibiotics, beta-lactam antibiotics ---> SmPC of [amikacine] of eMC

In vitro admixture of aminoglycosides with beta-lactam antibiotics (penicillins or cephalosporins) may result in significant mutual inactivation.

Aminoglycoside antibiotics, biphosphonates ---> SmPC of [ibandronic acid] of EMA

Caution is advised when bisphosphonates are administered with aminoglycosides, since both substances can lower serum calcium levels for prolonged periods. Attention should also be paid to the possible existence of simultaneous hypomagnesaemia.

Aminoglycoside antibiotics, botulinum toxin type A [2] ---> SmPC of [2] of EMA

Theoretically, the effect of botulinum toxin may be potentiated by aminoglycoside antibiotics, spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking medicinal products).

Aminoglycoside antibiotics, botulinum toxin type B [2] ---> SmPC of [2] of EMA

Co-administration of the toxin and aminoglycosides or agents interfering with neuromuscular transmission should be considered with caution.

Aminoglycoside antibiotics, botulinus toxin

Co-administration of the toxin and aminoglycosides or agents interfering with neuromuscular transmission should be considered with caution.

Aminoglycoside antibiotics, breast-feeding

Contraindicated

Aminoglycoside antibiotics, buclizine

Buclizine may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, bumetanide [2] ---> SmPC of [2] of eMC

Bumetanide should be used with caution in patients already receiving nephrotoxic or ototoxic drugs.

Aminoglycoside antibiotics, calcium chloride

The calcium chloride injection may abolish the neuromuscular blocking of aminoglycoside antibiotic

Aminoglycoside antibiotics, carboplatin [2] ---> SmPC of [2] of eMC

Concurrent therapy of carboplatin with nephrotoxic/ototoxic drugs such as aminoglycoside is not recommended, since this may lead to increased/exacerbated toxicity due to carboplatin induced changes in renal clearance of these substances

Aminoglycoside antibiotics, cefadroxil

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, cefalotin ---> SmPC of [gentamicin] of eMC

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, cefazolin

The combination of cefazolin with nephrotoxic drugs may potentiate the nephrotoxicity. Monitoring of renal function is recommended

Aminoglycoside antibiotics, cefixime

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, cefotaxime [2] ---> SmPC of [2] of eMC

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, cefpodoxime

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, ceftazidime [2] ---> SmPC of [2] of eMC

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, ceftriaxone [2] ---> SmPC of [2] of eMC

No interference with the action or increase in nephrotoxicity of aminoglycosides has been observed during simultaneous administration with ceftriaxone.

Aminoglycoside antibiotics, cefuroxime

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, cephalosporins

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function

Aminoglycoside antibiotics, cephalosporins ---> SmPC of [amikacine] of eMC

Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins.

Aminoglycoside antibiotics, chlortetracycline

The co-administration of bactericide with bacteriostatic antibiotics should be avoided due to possible antagonist effects

Aminoglycoside antibiotics, cisatracurium [2] ---> SmPC of [2] of eMC

Antibiotics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents

Aminoglycoside antibiotics, cisplatin [2] ---> SmPC of [2] of eMC

Concomitant administration of cisplatin and nephrotoxic and ototoxic medicinal products will potentiate the toxic effect of cisplatin on the kidneys and on auditory function

Aminoglycoside antibiotics, citrate

Enhancement of a neuromuscular block or respiratory paralysis by transfussion with anticoagulated blood with citrate

Aminoglycoside antibiotics, clindamycin ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with clindamycin may increase the risk of nephrotoxicity

Aminoglycoside antibiotics, clodronate [2] ---> SmPC of [2] of eMC

As aminoglycosides can cause hypocalcaemia concomitant clodronate should be administered with caution.

Aminoglycoside antibiotics, clodronic acid [2] ---> SmPC of [2] of eMC

As aminoglycosides can cause hypocalcaemia concomitant clodronate should be administered with caution.

Aminoglycoside antibiotics, clofarabine [2] ---> SmPC of [2] of EMA

The concomitant use of medicinal products that have been associated with renal toxicity should be avoided

Aminoglycoside antibiotics, colistimethate [2] ---> SmPC of [2] of EMA

Concomitant use of inhaled colistimethate sodium with other medications that are potentially nephrotoxic or neurotoxic should be undertaken with caution.

Aminoglycoside antibiotics, colistin ---> SmPC of [amikacine] of eMC

The administration concurrent or sequential of polypeptide antibiotics with aminoglycoside antibiotics may increase the risk of nephrotoxicity and/or of neuromuscular blockade that can cause respiratory depression or paralysis (apnea)

Aminoglycoside antibiotics, curare-type muscle relaxants

Neuromuscular blockade and respiratory paralysis have been reported from administration of aminoglycosides to patients who have received curare-type muscle relaxants during anaesthesia.

Aminoglycoside antibiotics, cyclizine

Cyclizine may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, cyclosporine [2] ---> SmPC of [2] of eMC

Care should be taken when using ciclosporin together with other active substances that exhibit nephrotoxic synergy

Aminoglycoside antibiotics, cytotoxic agents ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with cytotoxic agents may increase the risk of nephrotoxicity

Aminoglycoside antibiotics, daunorubicin ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with cytotoxic agents may increase the risk of nephrotoxicity

Aminoglycoside antibiotics, decamethonium

Enhancement of a neuromuscular block or respiratory paralysis

Aminoglycoside antibiotics, depolarizing muscle relaxants

Concurrent administration of aminoglycoside antibiotics with neuromuscular blockers may enhance the neuromuscular blockade

Aminoglycoside antibiotics, dexibuprofen

Co-administration of aminoglycoside antibiotics with NSAIDs may increase the risk of nephrotoxicity on account of reduced synthesis of prostaglandins in the kidney. During combination treatment renal function must be closely monitored

Aminoglycoside antibiotics, dexketoprofen [2] ---> SmPC of [2] of eMC

In some patients with compromised renal function, the coadministration may result in further deterioration of renal function, which is usually reversible.

Aminoglycoside antibiotics, dimenhydrinate

The co-administration may mask the symptome of ototoxicity

Aminoglycoside antibiotics, dimethyl fumarate [2] ---> SmPC of [2] of EMA

Concurrent therapy of dimethyl fumarate with nephrotoxic medicinal may increase the potential of renal adverse reactions (e.g. proteinuria)

Aminoglycoside antibiotics, doravirine/lamivudine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Due to the tenofovir disoproxil component of doravirine/lamivudine/tenofovir disoproxil, use of the product should be avoided with concurrent or recent use of nephrotoxic medicinal products.

Aminoglycoside antibiotics, doxylamine

Antihistaminics may mask the ototoxic effects of other drugs

Aminoglycoside antibiotics, emtricitabine [2] ---> SmPC of [2] of EMA

Use of emtricitabine should be avoided with concurrent or recent use of a nephrotoxic medicinal product

Aminoglycoside antibiotics, emtricitabine/rilpivirine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Use of emtricitabine/rilpivirine/tenofovir should be avoided with concurrent or recent use of a nephrotoxic medicinal product

Aminoglycoside antibiotics, emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Use of Truvada should be avoided with concurrent or recent use of a nephrotoxic medicinal product

Aminoglycoside antibiotics, escin

Concomitant use should be avoided. The nephrotoxicity of aminoglycoside antibiotic may increase.

Aminoglycoside antibiotics, ether

The neuromuscular blocking properties of aminoglycoside antibiotics are potentiated by ether

Aminoglycoside antibiotics, etidronate

Enhancement of the hypocalcemic effect

Aminoglycoside antibiotics, etidronic acid

Enhancement of the hypocalcemic effect

Aminoglycoside antibiotics, flucloxacillin

The co-administration may have a synergistic effect

Aminoglycoside antibiotics, foscarnet [2] ---> SmPC of [2] of eMC

Since foscarnet can impair renal function, additive toxicity may occur when used in combination with other nephrotoxic drugs

Aminoglycoside antibiotics, fosfomycin

The combination of fosfomycin with aminoglycoside antibiotics usually shows an additive to synergistic effect.

Aminoglycoside antibiotics, framycetin

The co-administration may enhance the ototoxic effect of both active principles. The combination should be avoided.

Aminoglycoside antibiotics, furosemide [2] ---> SmPC of [2] of eMC

Increased risk of ototoxicity and nephrotoxicity with aminoglycosides. Concomitant use should be avoided

Aminoglycoside antibiotics, general anesthetics

Care is required when patients being treated with aminoglycosides are to receive a general anaesthetic or opioids in order to avoid the possible neuromuscular side-effects provoking severe respiratory depression.

Aminoglycoside antibiotics, gentamicin [2] ---> SmPC of [2] of eMC

Concurrent administration of gentamicin and other potentially ototoxic or nephrotoxic drugs should be avoided.

Aminoglycoside antibiotics, halogenated anaesthetics

Halogenated anaesthetics may potentiate the neuromuscular block

Aminoglycoside antibiotics, halothane

Enhancement of a neuromuscular block or respiratory paralysis

Aminoglycoside antibiotics, hydroxychloroquine [2] ---> SmPC of [2] of eMC

The aminoglycoside antibiotic may enhance the direct blocking action of the hydroxychloroquine at the neuromuscular junction

Aminoglycoside antibiotics, ibuprofen [2] ---> SmPC of [2] of EMA

Ibuprofen may decrease the clearance of aminoglycosides and increase the risk of nephrotoxicity and ototoxicity. Co-administration is not recommended

Aminoglycoside antibiotics, ifosfamide

The previous or concomitant treatment of nephrotoxic drugs may enhance the nephrotoxicity of ifosfamide and thus also the hematotoxicity and CNS toxicity

Aminoglycoside antibiotics, immunosuppressives ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with immunosuppresive agents may increase the risk of nephrotoxicity

Aminoglycoside antibiotics, indometacin ---> SmPC of [gentamicin] of eMC

Concurrent administration of aminoglycoside antibiotics with indometacin may decrease the renal clearance of antibiotic with risk of toxicity

Aminoglycoside antibiotics, loop diuretics

The co-administration may enhance the ototoxicity and/or nephrotoxicity

Aminoglycoside antibiotics, loxapine ---> SmPC of [gentamicin] of eMC

Loxapine may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, meclozine

Meclozine may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, meglumine and sodium ioxitalamate

The co-administration with other medicinal products with nephrotoxic potential may decrease the renal function and cause a permanent damage

Aminoglycoside antibiotics, mesna

Mesna inactivates the aminoglycoside antibiotic

Aminoglycoside antibiotics, methoxyflurane ---> SmPC of [amikacine] of eMC

Concurrent administration of aminoglycoside antibiotics with methoxyflurane may increase the risk of nephrotoxicity. The concurrent administration should be avoided

Aminoglycoside antibiotics, mezlocillin

The co-administration may have a synergistic effect

Aminoglycoside antibiotics, mivacurium [2] ---> SmPC of [2] of eMC

As all non-depolarising neuromuscular blocking agents, the magnitude and/or duration of non-depolarising neuromuscular block may be increased and infusion requirements may be reduced as a result of interaction with antibiotics

Aminoglycoside antibiotics, muscle relaxants

Concurrent administration of aminoglycoside antibiotics with neuromuscular blockers may enhance the neuromuscular blockade

Aminoglycoside antibiotics, muscle relaxants (non-depolarizing) ---> SmPC of [atracurium] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with antibiotics

Aminoglycoside antibiotics, neomycin

Care should be taken when considering the use of neomycin concurrently with drugs with a potential to cause nephrotoxicity

Aminoglycoside antibiotics, neostigmine

The effect of neostigmine may be antagonised by aminoglycosides.

Aminoglycoside antibiotics, nephrotoxic substances

The concomitant use of the aminoglycoside antibiotic with medicinal products that have been associated with renal toxicity should be avoided

Aminoglycoside antibiotics, netilmicin

The administration concurrent or sequential of netilmicin with other potentially nephrotoxic or neurotoxic drugs may increase the nephrotoxicity and/or neurotoxicity

Aminoglycoside antibiotics, neurotoxic substances

The concomitant use of the aminoglycoside antibiotic with medicinal products that have been associated with neurotoxicity should be avoided

Aminoglycoside antibiotics, nimodipine

The co-administration of nimodipine with potential nephrotoxic agents may impairment the renal function

Aminoglycoside antibiotics, NSAID ---> SmPC of [dexibuprofen] of eMC

Co-administration of aminoglycoside antibiotics with NSAIDs may increase the risk of nephrotoxicity on account of reduced synthesis of prostaglandins in the kidney. During combination treatment renal function must be closely monitored

Aminoglycoside antibiotics, opiate agonists

Care is required when patients being treated with aminoglycosides are to receive a general anaesthetic or opioids in order to avoid the possible neuromuscular side-effects provoking severe respiratory depression.

Aminoglycoside antibiotics, oral anticoagulants

There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.

Aminoglycoside antibiotics, ototoxic agents

The concomitant use of the aminoglycoside antibiotic with medicinal products that have been associated with ototoxicity should be avoided

Aminoglycoside antibiotics, pancuronium [2] ---> SmPC of [2] of eMC

Potentiation of the duration of action of pancuronium and the intensity of neuromuscular block.

Aminoglycoside antibiotics, pemetrexed [2] ---> SmPC of [2] of EMA

Concomitant administration of nephrotoxic can potentially delay the clearance of pemetrexed. The combination should be used with caution

Aminoglycoside antibiotics, penicillins ---> SmPC of [amikacine] of eMC

In vitro admixture of aminoglycosides with beta-lactam antibiotics (penicillins or cephalosporins) may result in significant mutual inactivation.

Aminoglycoside antibiotics, phenothiazines ---> SmPC of [amikacine] of eMC

Phenothiazines may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, phenoxymethylpenicillin

Significant mutual inactivation

Aminoglycoside antibiotics, phenprocoumon

Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of oral aminoglycoside antibiotics

Aminoglycoside antibiotics, piretanide

The co-administration may enhance the ototoxicity and/or nephrotoxicity

Aminoglycoside antibiotics, platinum compounds

There is an increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides are administered with platinum compounds.

Aminoglycoside antibiotics, polymyxin ---> SmPC of [amikacine] of eMC

The administration concurrent or sequential of polypeptide antibiotics with aminoglycoside antibiotics may increase the risk of nephrotoxicity and/or of neuromuscular blockade that can cause respiratory depression or paralysis (apnea)

Aminoglycoside antibiotics, polypeptide antibiotics ---> SmPC of [amikacine] of eMC

The administration concurrent or sequential of polypeptide antibiotics with aminoglycoside antibiotics may increase the risk of nephrotoxicity and/or of neuromuscular blockade that can cause respiratory depression or paralysis (apnea)

Aminoglycoside antibiotics, pregnancy ---> SmPC of [amikacine] of eMC

The aminoglycoside antibiotic crosses the placenta

Aminoglycoside antibiotics, procainamide

Enhancement of a neuromuscular block or respiratory paralysis

Aminoglycoside antibiotics, pyridostigmine

The effect of pyridostigmine may be antagonised by aminoglycosides.

Aminoglycoside antibiotics, rocuronium [2] ---> SmPC of [2] of eMC

Recurarisation has been reported after post-operative administration of aminoglycoside

Aminoglycoside antibiotics, strong diuretic agents ---> SmPC of [bumetanide] of eMC

Ototoxic effects of aminoglycosides may be increased during the treatment with strong diuretics

Aminoglycoside antibiotics, succinylcholine ---> SmPC of [suxamethonium] of eMC

Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.

Aminoglycoside antibiotics, suxamethonium [2] ---> SmPC of [2] of eMC

Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.

Aminoglycoside antibiotics, tacrolimus [2] ---> SmPC of [2] of EMA

Concurrent use of tacrolimus with medicinal products known to have nephrotoxic or neurotoxic effects may increase these effects

Aminoglycoside antibiotics, teicoplanin [2] ---> SmPC of [2] of eMC

Teicoplanin should be used with care in conjunction with or sequentially with other medicinal products with known nephrotoxic or ototoxic potential.

Aminoglycoside antibiotics, telbivudine [2] ---> SmPC of [2] of EMA

Since telbivudine is eliminated primarily by renal excretion, co-administration with substances that affect renal function may affect plasma concentrations of telbivudine and/or the co-administered substance. The combination should be used with caution.

Aminoglycoside antibiotics, tenofovir disoproxil [2] ---> SmPC of [2] of EMA

Use of tenofovir should be avoided with concurrent or recent use of a nephrotoxic medicinal product

Aminoglycoside antibiotics, tetracyclines

The co-administration of bactericide with bacteriostatic antibiotics should be avoided due to possible antagonist effects

Aminoglycoside antibiotics, thioxanthenes ---> SmPC of [amikacine] of eMC

Thioxanthenes may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, ticarcillin/clavulanic acid

The co-administration may have a synergistic effect

Aminoglycoside antibiotics, tiopronin

Increased risk of nephrotoxicity and ototoxicity

Aminoglycoside antibiotics, tobramycin [2] ---> SmPC of [2] of EMA

The co-administration with parenteral aminoglycoside therapy should be monitored taking into account the risk of cumulative toxicity

Aminoglycoside antibiotics, torasemid [2] ---> SmPC of [2] of eMC

Torasemide, especially at high doses, may potentiate the toxicity of aminoglycoside antibiotics

Aminoglycoside antibiotics, trimethobenzamide

Trimethobenzamide may mask the ototoxicity symptoms of aminoglycoside antibiotics

Aminoglycoside antibiotics, tubocuranine

The aminoglycoside antibiotic may enhance the effect of muscle relaxant agent

Aminoglycoside antibiotics, valaciclovir [2] ---> SmPC of [2] of eMC

The combination of valaciclovir with nephrotoxic medicinal products should be made with caution, especially in subjects with impaired renal function, and warrants regular monitoring of renal function.

Aminoglycoside antibiotics, vancomycin [2] ---> SmPC of [2] of eMC

If vancomycin is co-administrated with an aminoglycoside (e.a. gentamycine) patients should be monitored carefully for signs of neurotoxicity and ototoxicity. The dosage should be adjusted when renal disturbance occurs

Aminoglycoside antibiotics, vecuronium [2] ---> SmPC of [2] of eMC

Recurarisation has been reported after post-operative administration of aminoglycoside antibiotics

Aminoglycoside antibiotics, xipamide

Increased risk of ototoxicity and nephrotoxicity

Aminoglycoside antibiotics, zoledronate [2] ---> SmPC of [2] of EMA

Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required.

Aminoglycoside antibiotics, zoledronic acid [2] ---> SmPC of [2] of EMA

Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required.

Antibiotics, anticoagulants

The co-administration may enhance the anticoagulant effect and increase the bleeding risk

Antibiotics, BCG intravesical [2] ---> SmPC of [2] of eMC

The anti-tumour activity may be influenced by concomitant therapy with antibiotics. It is recommended to postpone the intravesical instillation until the end of the antibiotic-treatment

Antibiotics, besilesomab [2] ---> SmPC of [2] of EMA

The combination may lead to false negative results. Such substances should not be administered together with, or a short time before the injection of besilesomab

Antibiotics, bisacodyl

The co-administration may decrease the laxative effect

Antibiotics, bromelain

The co-administration may increase the tissue levels of antibiotic agent

Antibiotics, cholera vaccine [2] ---> SmPC of [2] of EMA

Concomitant administration with antibacterial agents and/or chloroquine should be avoided because protection against cholera may be diminished.

Antibiotics, cisatracurium [2] ---> SmPC of [2] of eMC

Antibiotics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents

Antibiotics, contraceptives

Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.

Antibiotics, deflazacort

It is important to ensure that any anti-infective therapy is effective and it is recommended to monitor patients closely.

Antibiotics, escin

The antibiotic may decrease the plasma protein binding of aescin and increase the plasma concentration of free aescin.

Antibiotics, estrogens

Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

Antibiotics, ethinylestradiol/desogestrel [2] ---> SmPC of [2] of eMC

Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibiotic agents are given, which may reduce ethinylestradiol concentrations (e.g., penicillins, tetracyclines).

Antibiotics, glucocorticoids

It is important to ensure that any anti-infective therapy is effective and it is recommended to monitor patients closely.

Antibiotics, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA

For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before or 4 hours after lixisenatide injection.

Antibiotics, laxatives

Loss of the laxative effect

Antibiotics, lixisenatide [2] ---> SmPC of [2] of EMA

For oral medicinal products that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before or 4 hours after lixisenatide injection.

Antibiotics, macimorelin [2] ---> SmPC of [2] of EMA

Co-administration of macimorelin with medicinal products with a potential to induce torsades de pointes should be avoided

Antibiotics, methotrexate [2] ---> SmPC of [2] of EMA

Antibiotics can, in individual cases, reduce the renal clearance of methotrexate, so that increased serum concentrations of methotrexate with simultaneous haematological and gastro-intestinal toxicity may occur.

Antibiotics, mivacurium [2] ---> SmPC of [2] of eMC

As all non-depolarising neuromuscular blocking agents, the magnitude and/or duration of non-depolarising neuromuscular block may be increased and infusion requirements may be reduced as a result of interaction with antibiotics

Antibiotics, norgestimate

The combination may decrease the effectiveness of norgestimate

Antibiotics, oral anticoagulants

The co-administration may increase the anticoagulant activity and increase the bleeding risk

Antibiotics, oral anticoagulants

It is recommended that the INR should be monitored as appropriate during and shortly after co-administration of antibiotics with oral anti-coagulant medicinal products.

Antibiotics, oral anticoagulants ---> SmPC of [meropenem/vaborbactam] of EMA

There have been many reports of increases in the anticoagulant effects of orally administered anticoagulants, including warfarin in patients, who are concomitantly receiving antibacterial agents.

Antibiotics, oral antidiabetics

The co-administration may enhance the antidiabetic effect

Antibiotics, oral contraceptives ---> SmPC of [tigecycline] of EMA

Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.

Antibiotics, regorafenib [2] ---> SmPC of [2] of EMA

The clinical significance of the neomycin interaction is unknown, but may result in a decreased efficacy of regorafenib. Pharmacokinetic interactions of other antibiotics have not been studied.

Antibiotics, sodium picosulfate [2] ---> SmPC of [2] of eMC

Concurrent administration of antibiotics may reduce the laxative action of this product.

Antibiotics, sorafenib [2] ---> SmPC of [2] of EMA

The risk of reduced plasma concentrations of sorafenib should be considered before starting a treatment course with antibiotics.

Antibiotics, sulfasalazine

The combination with antibiotics may decrease the sulfasalazine effect due to partial inhibition of bacterial metabolism because of reduction of gastrointestinal flora

Antibiotics, tigecycline [2] ---> SmPC of [2] of EMA

In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes.

Antibiotics, tocofersolan [2] ---> SmPC of [2] of EMA

Due to inhibition of P-Glycoprotein transporter, tocofersolan may also enhance intestinal absorption of highly lipophilic medicinal products. Therefore, monitoring should be performed and, when necessary, doses should be adjusted.

Antibiotics, tuberculosis vaccine

BCG bacteria are susceptible to antibiotic agents

Antibiotics, typhoid vaccine

Oral typhoid vaccine is inactivated by concomitant antibiotic administration.

Antibiotics, warfarin

Simultaneous administration of antibacterial agents with warfarin may augment its anticoagulant effects.

Antibiotics, warfarin ---> SmPC of [imipenem/cilastatin] of eMC

There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.

Benperidol, polypeptide antibiotics

Enhancement of the respiratory depression caused by the polypeptide antibiotic

Broad-spectrum antibiotics, methotrexate [2] ---> SmPC of [2] of EMA

Oral antibiotics and non-absorbable broad-spectrum antibiotics may reduce intestinal methotrexate absorption or interfere with the enterohepatic circulation, due to inhibition of the intestinal flora or suppression of bacterial metabolism.

Bromperidol, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by bromperidol

Chlorprothixene, polypeptide antibiotics

Chlorprothixene may enhance the respiratory depression caused by the polypeptide antibiotic

Flupentixol, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by flupentixol

Fluphenazine, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by fluphenazine

Fluspirilene, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by fluspirilene

Gentamicin, polypeptide antibiotics

The administration concurrent or sequential of polypeptide antibiotics with aminoglycoside antibiotics may increase the risk of nephrotoxicity and/or of neuromuscular blockade that can cause respiratory depression or paralysis (apnea)

Glycopeptide antibiotics, methotrexate [2] ---> SmPC of [2] of EMA

Antibiotics can, in individual cases, reduce the renal clearance of methotrexate, so that increased serum concentrations of methotrexate with simultaneous haematological and gastro-intestinal toxicity may occur.

Haloperidol, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by haloperidol

Levomepromazine, polypeptide antibiotics

Phenothiazines may enhance a central respiratory depression in conjunction with polypeptide antibiotics

Netilmicin, polypeptide antibiotics

The administration concurrent or sequential of netilmicin with other potentially nephrotoxic or neurotoxic drugs may increase the nephrotoxicity and/or neurotoxicity

Pancuronium, polypeptide antibiotics [2] ---> SmPC of [2] of eMC

Potentiation of the duration of action of pancuronium and the intensity of neuromuscular block.

Perphenazine, polypeptide antibiotics

The respiratory depression caused by the polypeptide antibiotic may be enhanced by perphenazine

Phenothiazines, polypeptide antibiotics

Phenothiazines may enhance a central respiratory depression in conjunction with polypeptide antibiotics

Polypeptide antibiotics, rocuronium [2] ---> SmPC of [2] of eMC

Recurarisation has been reported after post-operative administration of polypeptide

Polypeptide antibiotics, succinylcholine ---> SmPC of [suxamethonium] of eMC

Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.

Polypeptide antibiotics, suxamethonium [2] ---> SmPC of [2] of eMC

Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.

Polypeptide antibiotics, thioxanthenes

Thioxanthenes combined with peptide antibiotics (e. g. capreomycin, colistin, polymyxin B) may enhance a central respiratory depression

Polypeptide antibiotics, vancomycin [2] ---> SmPC of [2] of eMC

Concurrent or sequential systemic or topical use of other potentially neurotoxic or nephrotoxic drugs may potentiate the nephrotoxicity and/or ototoxicity of vancomycin and consequently requires careful monitoring.

Polypeptide antibiotics, vecuronium [2] ---> SmPC of [2] of eMC

Recurarisation has been reported after post-operative administration of polypeptide antibiotics

Polypeptide antibiotics, zuclopenthixol

Thioxanthenes combined with peptide antibiotics (e. g. capreomycin, colistin, polymyxin B) may enhance a central respiratory depression